Category: Health
The first study would showcase the expression of CCR5 as a new biomarker in metastatic Breast Cancer’s Circulating Tumor Cells. The second study would showcase the ability of Leronlimab as a CCR5 Inhibitor that can block metastatic Breast Cancer. CytoDyn, a renowned Vancouver-based biotechnology firm, …
The results would help in supporting the contribution of ipatasertib to the firm’s approach of combination treatment in TNBC Reports confirms that Roche will be presenting the initial results from a study of Phase Ib that evaluates the safety and efficacy for the combination of …
The updates were informed by newly published research covering results from REDUCE-IT trial and were crafted and approved by the Professional Practice Committee of ADA Pharmaceutical company Amarin Corporation plc has recently confirmed that important updates have been issued by the American Diabetes Association (ADA) …
The authorized regulators have acknowledged the choice of pathway for conditional marketing authorization. Santhera Pharmaceuticals has announced its intention of filing an application with European Medicines Agency (EMA) for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) to treat respiratory dysfunction in Duchenne muscular dystrophy (DMD). …
Apealea’s marketing authorization approval in the EEA was given on the basis of phase III pivotal study OAS‑07OVA Oasmia Pharmaceutical has reportedly announced that European Medicines Agency (EMA) has given a positive opinion and has recommended the approval of a type II variation application for …
Grifols S.A., the leading Spanish pharmaceutical & chemical manufacturer, has reportedly entered into a definitive agreement to acquire a major stake worth $1.9 billion in Shanghai RAAS Blood Products Co. With the latest move, Grifols is endeavoring to consolidate its foothold in China’s flourishing blood …
Sarepta’s resolve to build its gene therapy engine has been reinforced with renewed purpose due to the positive results obtained in the first MYO-101 cohort, says CEO Doug Ingram. Sarepta Therapeutics, Inc., one of the leaders in precision genetic medicine, recently announced that the clinical …
The new patent will be valid until 2038 while the firm expects to present ongoing study reports by the second half of 2019. Zynerba Pharmaceuticals, Inc., the leading developer of innovative pharmaceutically-produced transdermal cannabinoid treatments designed for treating rare and near-rare neuropsychiatric disorders, has recently …
